Merck & Co., Inc. Release: ISENTRESS® (raltegravir) in Combination Therapy Demonstrated Long-Term Efficacy and Safety in Adult Patients Co-Infected With HIV-1 and Hepatitis B and/or C in a Subgroup Analysis at 240 Weeks

GLASGOW, United Kingdom--(BUSINESS WIRE)--MSD, known as Merck in the United States and Canada, today presented new data from a post-hoc, subgroup analysis of three double-blind clinical trials, which found ISENTRESS® (raltegravir) demonstrated consistent long-term viral suppression and a well established safety profile in adult patients co-infected with HIV-1 and hepatitis C (HCV) and/or hepatitis B (HBV) when compared to adult patients with HIV-1 at 240 weeks. These studies were conducted in previously untreated or treatment-naïve (STARTMRK study) and treatment-experienced (BENCHMRK-1 and -2 studies) adult patients with HIV-1. The study results were presented during a poster discussion at the 11th International Congress on HIV and Drug Therapy in HIV Infection (HIV 11) in Glasgow, Scotland (Poster # P127).